Gene therapy for oral squamous cell carcinoma with IAI.3B promoter-driven oncolytic adenovirus-infected carrier cells

Oncology Reports

Volumn 25, Issue 3, 2011, Pages 795-802

  Zhang, Ting ^a   Hamada, Katsuyuki ^a   Hyodo, Masamitsu ^b   Itoh, Hiroshi ^c   Tani, Kenzaburo ^d   Goda, Hiroyuki ^a   Nakashiro, Koh Ichi ^a   Hamakawa, Hiroyuki ^a  

^a EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KOCHI MEDICAL SCHOOL   (Japan)

^c TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (Japan)

^d KYUSHU UNIVERSITY HOSPITAL   (Japan)

Author keywords

Carrier cell; IAI.3B; Oncolytic adenovirus; Oral squamous cell carcinoma; Promoter

Indexed keywords

ADENOVIRUS VECTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; NEUTRALIZING ANTIBODY; ONCOLYTIC ADENOVIRUS;

ADENOVIRUS; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER REGRESSION; CELL LINE; CELL STRAIN A549; CONTROLLED STUDY; GENE; GENE ACTIVATION; GENE THERAPY; HUMAN; IAI.3B GENE; IMMUNIZATION; IMMUNOGENICITY; IN VITRO STUDY; MOUSE; MOUTH CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; SQUAMOUS CELL CARCINOMA;

ADENOVIRIDAE; ANIMALS; CARCINOMA, SQUAMOUS CELL; CELLS, CULTURED; GENE THERAPY; GENETIC VECTORS; HELA CELLS; HT29 CELLS; HUMANS; MICE; MICE, NUDE; MOUTH NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PROMOTER REGIONS, GENETIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79551594080     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2010.1130     Document Type: Article

References (22)

1. Geoerger B, Grill J, Opolon P, et al: Oncolytic activity of the E1B-55kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts. Cancer Res 62: 764-772, 2002.
2. DeMatteo RP, Yeh H, Friscia M, et al: Cellular immunity delimits adenoviral therapy strategies for the treatment of neoplastic diseases. Ann Sur Oncol 6: 88-94, 1999.
3. Mok H, Palmer DJ, Ng P and Barry MA: Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce immune responses. Mol Ther 11: 66-79, 2005.
4. Yotnda P, Chen DH, Chiu W, et al: Bilamellar cationic liposomes protect adenovectors from preexisting humoral immune responses. Mol Ther 5: 233-241, 2002.
5. Bouvet M, Fang B, Ekmekcioglu S, et al: Suppression of the immune response to an adenovirus vector and enhancement of intratumoral transgene expression by low-dose etoposide. Gene Ther 5: 189-195, 1998.
6. Jooss K, Yang Y and Wilson JM: Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung. Hum Gene Ther 20: 1555-1566, 1996.
7. Coukos G, Makrigiannakis A, Kang EH, et al: Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer. Clin Cancer Res 5: 1523-1537, 1999.
8. Garcia-Castro J, Martinez-Palacio J, Lillo R, et al: Tumor cells as cellular vehicles to deliver gene therapies to metastatic tumors. Cancer Gene Ther 12: 341-349, 2005.
9. Hakkrainen T, Sarkioja M, Lehenkari P, et al: Human mesenchymal stem cells lack tumor tropism but enhance the antitumor activity of oncolytic adenoviruses in orthotopic lung and breast tumors. Human Gene Ther 18: 627-641, 2007.
10. Munguia A, Ota T, Miest T and Russell SJ: Cell carriers to deliver oncolytic viruses to sites of myeloma tumor growth. Gene Ther 15: 797-806, 2008.
11. Thorne SH, Negrin RS and Contag CH: Synergistic antitumor effects of immune cell-viral biotherapy. Science 311: 1780-1784, 2006.
12. Raykov Z, Balboni G, Aprahamaian M and Rommelaere J: Carrier cell-mediated delivery of oncolytic parvoviruses for targeting metastases. Int J Cancer 109: 742-749, 2004.
13. Power AT, Wang J, Falls TJ, et al: Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity. Mol Ther 15: 123-130, 2007.
14. Qiao J, Kottke T, Willmon C, et al: Purging metastases in lymphoid organs using a combination of antigen-non-specific adoptive T cell therapy, oncolytic virotherapy and immunotherapy. Nat Med 14: 37-44, 2007.
15. Hamada K, Desaki J, Nakagawa K, Shirakawa T, Gotoh A and Tagawa M: Carrier cell-mediated infection of a replication-competent adenovirus for cancer gene therapy. Mol Ther 15: 1121-1128, 2007.
16. Campbell IG, Nicolai HM, Foulkes WD, et al: A novel gene encoding a B-box protein within the BRCA1 region at 17q21.1. Hum Mol Genet 3: 589-594, 1994.
17. Hamada K, Kohno S, Iwamoto M, et al: Identification of the human IAI.3B promoter element and its use in the construction of a replication-selective adenovirus for ovarian cancer therapy. Cancer Res 63: 2506-2512, 2003.
18. Miller CG, Krummenacher C, Eisenberg RJ, Cohen GH and Fraser NW: Development of a syngeneic murine B16 cell line-derived melanoma susceptible to destruction by neuro-attenuated HSV-1. Mol Ther 3: 160-168, 2000.
19. Tuzynski MH, Thal L, Pay M, et al: A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 11: 551-555, 2005.
20. Rachakatla RS, Marini F, Weiss ML, Tamura M and Troyer D: Development of human umbilical cord matrix stem cell-based gene therapy for experimental lung tumors. Cancer Gene Ther 14: 828-835, 2007.
21. Clayman GL, el-Naggar AK, Lippman SM, et al: Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol 16: 2231-2231, 1998.
22. Nemunaitis J, Khuri F, Ganly I, et al: Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol 19: 289-298, 2001.